Michael Kleinemeier Chairman of the Merck Supervisory Board until the 2024 AGM

Our Supervisory Board has elected Michael Kleinemeier (66) as its Chairman. He was Member of the SAP SE Executive Board from 2015 to 2020.

DARMSTADT, GERMANY — Merck, a leading science and technology company, today announced that the Supervisory Board has elected Michael Kleinemeier (66) as its Chair. Among other roles, Kleinemeier was a member of the Executive Board of SAP SE, Walldorf, as Head of SAP Digital Business Services from 2015 to 2020. He has been a member of the Merck Supervisory Board since 2019. The election of a new Chair of the Supervisory Board was required because the former Chair, Dr. Wolfgang Büchele, took on the role of Chair of the Board of Partners of E. Merck KG at the end of January 2024 and therefore resigned early from his position in the Supervisory Board.

Michael Kleinemeier will serve as Chair of the Supervisory Board until April 26, 2024, when the Merck Annual General Meeting is scheduled to elect six new shareholder representatives to the Supervisory Board. The Supervisory Board position made vacant by the departure of Wolfgang Büchele will then be newly filled and another Supervisory Board member will be elected. Until then, the Supervisory Board will temporarily operate with 15 members instead of the usual 16. After the 2024 Annual General Meeting, the new Supervisory Board will elect a chairperson.

Michael Kleinemeier will continue to serve as a Member of the Board of Partners of E. Merck KG.

About Merck

Merck, a leading science and technology company, operates across life science, healthcare and electronics. More than 64,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2022, Merck generated sales of € 22.2 billion in 66 countries.

Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as MilliporeSigma in life science, EMD Serono in healthcare, and EMD Electronics in electronics.

< | >